79 Vbwg PPTs View free & download

VBWG - The Sixth Organization to Assess Strategies in Acute Ischemic ... Current/former smoker. Placebo/UFH (n = 6056) OASIS-6 Trial Group. JAMA. 2006;295:1519-30. ...

The Sixth Organization to Assess Strategies in Acute Ischemic ... Current/former smoker. Placebo/UFH (n = 6056) OASIS-6 Trial Group. JAMA. 2006;295:1519-30. ...

| PowerPoint PPT presentation | free to view

VBWG - OASIS-5. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial ... MICHELANGELO OASIS 5 Steering Committee. Am Heart J. 2005;150:1107-14. ...

OASIS-5. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial ... MICHELANGELO OASIS 5 Steering Committee. Am Heart J. 2005;150:1107-14. ...

| PowerPoint PPT presentation | free to view

VBWG Report Figures for Dzau and Luscher PowerPoint PPT Presentation

VBWG Report Figures for Dzau and Luscher - DHA inhibits IL-1 -mediated induction. of COX-2 activity. 6-keto-PGF1a* % of IL-1 control ... P 0.05; P 0.01. DHA = docosahexaenoate acid, an omega-3 fatty acid ...

DHA inhibits IL-1 -mediated induction. of COX-2 activity. 6-keto-PGF1a* % of IL-1 control ... P 0.05; P 0.01. DHA = docosahexaenoate acid, an omega-3 fatty acid ...

| PowerPoint PPT presentation | free to view

Management Strategies for Post-Intervention in Patients with CAD PowerPoint PPT Presentation

Management Strategies for Post-Intervention in Patients with CAD - VBWG Management Strategies for Post-Intervention in Patients with CAD

VBWG Management Strategies for Post-Intervention in Patients with CAD

| PowerPoint PPT presentation | free to view

Potential role of PPAR activation in CV risk reduction PowerPoint PPT Presentation

Potential role of PPAR activation in CV risk reduction - VBWG. Potential role of PPAR activation. in CV ... 2003;302:406-7. Peroxisome proliferator-activator. receptors ... Pioglitazone Actos Eli Lilly/ 1999 Takeda ...

VBWG. Potential role of PPAR activation. in CV ... 2003;302:406-7. Peroxisome proliferator-activator. receptors ... Pioglitazone Actos Eli Lilly/ 1999 Takeda ...

| PowerPoint PPT presentation | free to view

Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial PowerPoint PPT Presentation

Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial - VBWG Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm Rationale Cardiovascular (CV) disease continues to be the chief ...

VBWG Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm Rationale Cardiovascular (CV) disease continues to be the chief ...

| PowerPoint PPT presentation | free to view

PROactive: Study design PowerPoint PPT Presentation

PROactive: Study design - Current therapy n (%) VBWG. PROactive: Reduction in primary outcome. Dormandy JA et al. ... Time from randomization (months) Proportion. of events ...

Current therapy n (%) VBWG. PROactive: Reduction in primary outcome. Dormandy JA et al. ... Time from randomization (months) Proportion. of events ...

| PowerPoint PPT presentation | free to view

Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial - VBWG *Amlodipine 5 10 mg perindopril 4 8 mg prn Atenolol 50 100 mg bendroflumethiazide 1.25 2.5 mg/potassium prn Atenolol-based regimen* Amlodipine ...

VBWG *Amlodipine 5 10 mg perindopril 4 8 mg prn Atenolol 50 100 mg bendroflumethiazide 1.25 2.5 mg/potassium prn Atenolol-based regimen* Amlodipine ...

| PowerPoint PPT presentation | free to view

Dyslipidemia in hypertensive adults: High prevalence, insufficient treatment PowerPoint PPT Presentation

Dyslipidemia in hypertensive adults: High prevalence, insufficient treatment - VBWG. Dyslipidemia in hypertensive adults: High prevalence, ... Genetic Epidemiology Network of Arteriopathy (GENOA) study. O'Meara JG et al. Arch Intern Med. ...

VBWG. Dyslipidemia in hypertensive adults: High prevalence, ... Genetic Epidemiology Network of Arteriopathy (GENOA) study. O'Meara JG et al. Arch Intern Med. ...

| PowerPoint PPT presentation | free to view

GEMINI: Change in HbA1c and insulin sensitivity PowerPoint PPT Presentation

GEMINI: Change in HbA1c and insulin sensitivity - VBWG. Bakris GL et al. JAMA. 2004;292:2227-36. Carvedilol. Metoprolol tartrate. P % (SD) ... 0.15 (0.04) HbA1c. GEMINI: Change in HbA1c. and insulin sensitivity ...

VBWG. Bakris GL et al. JAMA. 2004;292:2227-36. Carvedilol. Metoprolol tartrate. P % (SD) ... 0.15 (0.04) HbA1c. GEMINI: Change in HbA1c. and insulin sensitivity ...

| PowerPoint PPT presentation | free to view

Difference in target dosing among ARB trials PowerPoint PPT Presentation

Difference in target dosing among ARB trials - VBWG. Difference in target dosing among ARB trials. Mortality trend favors captopril ... Placebo conventional HF Rx. HF. Val-HeFT. Similar mortality/morbidity ...

VBWG. Difference in target dosing among ARB trials. Mortality trend favors captopril ... Placebo conventional HF Rx. HF. Val-HeFT. Similar mortality/morbidity ...

| PowerPoint PPT presentation | free to download

WHI-OS: Baseline characteristics PowerPoint PPT Presentation

WHI-OS: Baseline characteristics - VBWG. Patients. Characteristic (N = 72,242) Age (yr) 63.1. White (%) 83.5. Diabetes (%) 4.5 ... 27.1. WHI-OS: Baseline characteristics. Margolis KL et al. Arch ...

VBWG. Patients. Characteristic (N = 72,242) Age (yr) 63.1. White (%) 83.5. Diabetes (%) 4.5 ... 27.1. WHI-OS: Baseline characteristics. Margolis KL et al. Arch ...

| PowerPoint PPT presentation | free to view

Background and objective PowerPoint PPT Presentation

Background and objective - VBWG. Background and objective. Margolis KL et al. Arch Intern Med. 2005;165:500-8. ... Background: Increasing evidence supports. a role for inflammation in the ...

VBWG. Background and objective. Margolis KL et al. Arch Intern Med. 2005;165:500-8. ... Background: Increasing evidence supports. a role for inflammation in the ...

| PowerPoint PPT presentation | free to view

Exercise reduces CV and all-cause mortality PowerPoint PPT Presentation

Exercise reduces CV and all-cause mortality - VBWG. Exercise reduces CV and all-cause mortality. Fang J et al. Am J Hypertens. 2005;18:751-8. N = 9791, moderate exercise vs little or no exercise ...

VBWG. Exercise reduces CV and all-cause mortality. Fang J et al. Am J Hypertens. 2005;18:751-8. N = 9791, moderate exercise vs little or no exercise ...

| PowerPoint PPT presentation | free to view

TNT: Incidence of elevated liver or muscle enzymes PowerPoint PPT Presentation

TNT: Incidence of elevated liver or muscle enzymes - VBWG. TNT: Incidence of elevated liver. or muscle enzymes. Atorvastatin. 80 mg (%) (n = 4995) ... P 0.001 vs atorvastatin 10 mg. ALT = alanine ...

VBWG. TNT: Incidence of elevated liver. or muscle enzymes. Atorvastatin. 80 mg (%) (n = 4995) ... P 0.001 vs atorvastatin 10 mg. ALT = alanine ...

| PowerPoint PPT presentation | free to view

Clinical Trials of GP IIbIIIa Inhibition PowerPoint PPT Presentation

Clinical Trials of GP IIbIIIa Inhibition - ESPRIT: Study design. Eptifibatide. 180- g/kg ... ESPRIT Investigators. ... ESPRIT: Primary outcome over time. VBWG. Lincoff AM et al. J Am Coll ...

ESPRIT: Study design. Eptifibatide. 180- g/kg ... ESPRIT Investigators. ... ESPRIT: Primary outcome over time. VBWG. Lincoff AM et al. J Am Coll ...

| PowerPoint PPT presentation | free to view

PROactive: CV medications at study entry PowerPoint PPT Presentation

PROactive: CV medications at study entry - VBWG. PROactive: CV medications at study entry. Dormandy JA et al. Lancet. 2005;366:1279-89. ... Thiazide diuretics. 43. 43. Statins. 40. 39. Nitrates. 83. 85 ...

VBWG. PROactive: CV medications at study entry. Dormandy JA et al. Lancet. 2005;366:1279-89. ... Thiazide diuretics. 43. 43. Statins. 40. 39. Nitrates. 83. 85 ...

| PowerPoint PPT presentation | free to view

ASCOT-BPLA: Summary PowerPoint PPT Presentation

ASCOT-BPLA: Summary - ASCOT-BPLA: Summary. VBWG. Dahl f B et al. Lancet. 2005;366:895-906. Poulter NR et al. Lancet. 2005;366:907-13. *mean in-trial systolic BP difference 2.7 mm Hg ...

ASCOT-BPLA: Summary. VBWG. Dahl f B et al. Lancet. 2005;366:895-906. Poulter NR et al. Lancet. 2005;366:907-13. *mean in-trial systolic BP difference 2.7 mm Hg ...

| PowerPoint PPT presentation | free to view

ACCAHA UANSTEMI Guidelines: Role of GP IIbIIIa Inhibitors PowerPoint PPT Presentation

ACCAHA UANSTEMI Guidelines: Role of GP IIbIIIa Inhibitors - ... should be administered in addition to ASA and heparin to patients in whom ... ASA or clopidogrel if ASA contraindicated. LMWH or UFH. GP IIb/IIIa inhibitor. VBWG ...

... should be administered in addition to ASA and heparin to patients in whom ... ASA or clopidogrel if ASA contraindicated. LMWH or UFH. GP IIb/IIIa inhibitor. VBWG ...

| PowerPoint PPT presentation | free to view

CHARISMA: Summary, contd PowerPoint PPT Presentation

CHARISMA: Summary, contd - VBWG. CHARISMA: Summary, cont'd. Symptomatic patients experienced a 12% reduction ... Overall, clopidogrel plus aspirin was not significantly more effective than ...

VBWG. CHARISMA: Summary, cont'd. Symptomatic patients experienced a 12% reduction ... Overall, clopidogrel plus aspirin was not significantly more effective than ...

| PowerPoint PPT presentation | free to view

Selected emerging biomarkers PowerPoint PPT Presentation

Selected emerging biomarkers - VBWG. Selected emerging biomarkers. Adapted from Stampfer ... Glutathione. Asp299Gly polymorphism. in TLR4 gene. MCP-1 2578G allele. CX3CR1 chemokine receptor ...

VBWG. Selected emerging biomarkers. Adapted from Stampfer ... Glutathione. Asp299Gly polymorphism. in TLR4 gene. MCP-1 2578G allele. CX3CR1 chemokine receptor ...

| PowerPoint PPT presentation | free to view

ASCOT: Patient population risk factor profile - VBWG. ASCOT: Patient population risk factor profile. Sever PS et al. Lancet. 2003;361:1149-58. ... LVH = left ventricular hypertrophy. All patients had ...

VBWG. ASCOT: Patient population risk factor profile. Sever PS et al. Lancet. 2003;361:1149-58. ... LVH = left ventricular hypertrophy. All patients had ...

| PowerPoint PPT presentation | free to view

New multifaceted approach to plaque stabilization PowerPoint PPT Presentation

New multifaceted approach to plaque stabilization - PowerPoint Presentation

PowerPoint Presentation

| PowerPoint PPT presentation | free to view

Interaction of hypercholesterolemia and inflammation in atherogenesis PowerPoint PPT Presentation

Interaction of hypercholesterolemia and inflammation in atherogenesis - Interaction of hypercholesterolemia. and inflammation in atherogenesis. Steinberg D. Nat Med. ... Fatty streak, made up mainly of cholesterol-rich foam cells ...

Interaction of hypercholesterolemia. and inflammation in atherogenesis. Steinberg D. Nat Med. ... Fatty streak, made up mainly of cholesterol-rich foam cells ...

| PowerPoint PPT presentation | free to view

Coagulation cascade: Central role of thrombin PowerPoint PPT Presentation

Coagulation cascade: Central role of thrombin - Coagulation cascade: Central role of thrombin. Fibrin. Fibrinogen. Factor. XIIIa. Platelets ... Thrombin. Reactivation. of coagulation. cascade. Vessel wall ...

Coagulation cascade: Central role of thrombin. Fibrin. Fibrinogen. Factor. XIIIa. Platelets ... Thrombin. Reactivation. of coagulation. cascade. Vessel wall ...

| PowerPoint PPT presentation | free to view

ACEI: Proposed continuum of benefits PowerPoint PPT Presentation

ACEI: Proposed continuum of benefits - Platelet inhibition. Cell proliferation and migration. Atherosclerotic plaque stabilization ... Immediate onset. Long-term effects. ACEI: Proposed continuum of ...

Platelet inhibition. Cell proliferation and migration. Atherosclerotic plaque stabilization ... Immediate onset. Long-term effects. ACEI: Proposed continuum of ...

| PowerPoint PPT presentation | free to view

Extension studies show sustained benefits with ACEI PowerPoint PPT Presentation

Extension studies show sustained benefits with ACEI - Characteristic Clinical HF, NYHA class IV HF, ... 174 study centers (n = 6786) HOPE-TOO participants. agreed to passive ... to all patients, independent of ...

Characteristic Clinical HF, NYHA class IV HF, ... 174 study centers (n = 6786) HOPE-TOO participants. agreed to passive ... to all patients, independent of ...

| PowerPoint PPT presentation | free to view

Updated guidelines: Classes of Recommendations and levels of evidence PowerPoint PPT Presentation

Updated guidelines: Classes of Recommendations and levels of evidence - A Data derived from. multiple randomized. clinical trials. B Data derived from. a single RCT or nonrandomized studies. C Consensus opinion ...

A Data derived from. multiple randomized. clinical trials. B Data derived from. a single RCT or nonrandomized studies. C Consensus opinion ...

| PowerPoint PPT presentation | free to view

Insert Title Here 3-Line Capacity (32 pt Arial Bold) Middle-Anchored - Insert Title Here 3Line Capacity 32 pt Arial Bold MiddleAnchored

Insert Title Here 3Line Capacity 32 pt Arial Bold MiddleAnchored

| PowerPoint PPT presentation | free to view

Ongoing Trials in Managing Myocardial Ischemia - Ongoing Trials in Managing Myocardial Ischemia

Ongoing Trials in Managing Myocardial Ischemia

| PowerPoint PPT presentation | free to view

Potential role of PPAR activation in CV risk reduction - in CV risk reduction Genetic background Food intake excess Physical inactivity Obesity Hyperglycemia Hyperinsulinemia Insulin Dyslipidemia Inflammation

in CV risk reduction Genetic background Food intake excess Physical inactivity Obesity Hyperglycemia Hyperinsulinemia Insulin Dyslipidemia Inflammation

| PowerPoint PPT presentation | free to view

Management Strategies for PostIntervention in Patients with CAD - Management Strategies for PostIntervention in Patients with CAD

Management Strategies for PostIntervention in Patients with CAD

| PowerPoint PPT presentation | free to view

ACEI trials in CAD without HF: Primary outcomes PowerPoint PPT Presentation

ACEI trials in CAD without HF: Primary outcomes - ACEI trials in CAD without HF: Primary outcomes. HOPE Study Investigators. N Engl J Med. ... Time (years) 1. 4% Risk increase. HR 1.04 (0.89 1.22) P = 0.6. 10 ...

ACEI trials in CAD without HF: Primary outcomes. HOPE Study Investigators. N Engl J Med. ... Time (years) 1. 4% Risk increase. HR 1.04 (0.89 1.22) P = 0.6. 10 ...

| PowerPoint PPT presentation | free to view

Measuring and Lowering Cholesterol PowerPoint PPT Presentation

Measuring and Lowering Cholesterol - ... 222 younger patients (men 55 and women 65) who were hospitalized for an acute MI ... individual curves. into sub-fractions ...

... 222 younger patients (men 55 and women 65) who were hospitalized for an acute MI ... individual curves. into sub-fractions ...

| PowerPoint PPT presentation | free to view

Risky Combos PowerPoint PPT Presentation

Risky Combos - Yes-! Healthful properties of tea are largely attributed to polyphenols ... Izzat MB et al. A taste of chinese medicine! Ann Thor Surg 1998;66:941-2. ...

Yes-! Healthful properties of tea are largely attributed to polyphenols ... Izzat MB et al. A taste of chinese medicine! Ann Thor Surg 1998;66:941-2. ...

| PowerPoint PPT presentation | free to view

Contemporary Management of Myocardial Ischemia PowerPoint PPT Presentation

Contemporary Management of Myocardial Ischemia - Growing prevalence of chronic ischemia (angina) due to residual CAD after PCI and CABG ... QTc 500msec: 10 patients; Torsade de Pointes: 0 patients ...

Growing prevalence of chronic ischemia (angina) due to residual CAD after PCI and CABG ... QTc 500msec: 10 patients; Torsade de Pointes: 0 patients ...

| PowerPoint PPT presentation | free to view

Practical Approaches to Managing Hypertension: Reducing Global Cardiovascular Risk PowerPoint PPT Presentation

Practical Approaches to Managing Hypertension: Reducing Global Cardiovascular Risk - Practical Approaches to Managing Hypertension: Reducing Global Cardiovascular Risk John S. Banas, MD Professor Emeritus of Clinical Medicine Columbia University ...

Practical Approaches to Managing Hypertension: Reducing Global Cardiovascular Risk John S. Banas, MD Professor Emeritus of Clinical Medicine Columbia University ...

| PowerPoint PPT presentation | free to view

Insulin Resistance and Cardiovascular Disease: PowerPoint PPT Presentation

Insulin Resistance and Cardiovascular Disease: - III. Insulin sensitizers: Surrogate and clinical. outcomes studies. IV. ... N = 266 Hispanic women with gestational diabetes randomized ...

III. Insulin sensitizers: Surrogate and clinical. outcomes studies. IV. ... N = 266 Hispanic women with gestational diabetes randomized ...

| PowerPoint PPT presentation | free to view

Slide 1 - Slide 1

Slide 1

| PowerPoint PPT presentation | free to view

No Slide Title PowerPoint PPT Presentation

No Slide Title - No Slide Title Created Date: 8/31/2000 8:30:39 PM Document presentation format: On-screen Show Company: MEDCON Other titles: Times Arial Blank Presentation PowerPoint ...

No Slide Title Created Date: 8/31/2000 8:30:39 PM Document presentation format: On-screen Show Company: MEDCON Other titles: Times Arial Blank Presentation PowerPoint ...

| PowerPoint PPT presentation | free to view

CHARM Program: 3 Component trials comparing candesartan with placebo PowerPoint PPT Presentation

CHARM Program: 3 Component trials comparing candesartan with placebo - Title: PowerPoint Presentation Author: William Tryon Created Date: 1/9/2003 10:52:48 PM Document presentation format: On-screen Show Other titles

Title: PowerPoint Presentation Author: William Tryon Created Date: 1/9/2003 10:52:48 PM Document presentation format: On-screen Show Other titles

| PowerPoint PPT presentation | free to view

No Slide Title - No Slide Title

No Slide Title

| PowerPoint PPT presentation | free to view

No Slide Title - Title: No Slide Title Author: William Tryon Last modified by: lmellgard Created Date: 8/31/2000 8:30:39 PM Document presentation format: 35mm Slides

Title: No Slide Title Author: William Tryon Last modified by: lmellgard Created Date: 8/31/2000 8:30:39 PM Document presentation format: 35mm Slides

| PowerPoint PPT presentation | free to view

No Slide Title - QUIET: Effect of quinapril on CAD progression according to LDL-C level A subanalysis of the QUIET data indicates that the beneficial effects of quinapril on ...

QUIET: Effect of quinapril on CAD progression according to LDL-C level A subanalysis of the QUIET data indicates that the beneficial effects of quinapril on ...

| PowerPoint PPT presentation | free to view

No Slide Title - No Slide Title

No Slide Title

| PowerPoint PPT presentation | free to view

New Frontiers in CVD Risk Management: Optimizing Outcomes in Patients with Multiple Cardiovascular Risks - New Frontiers in CVD Risk Management: Optimizing Outcomes in Patients with Multiple Cardiovascular Risks

New Frontiers in CVD Risk Management: Optimizing Outcomes in Patients with Multiple Cardiovascular Risks

| PowerPoint PPT presentation | free to view

Slide 1 - * B. Vascular dysfunction of the failing heart: Impact of neurohormonal blockade Strategies to prevent/reverse HF progression Content points: Maladaptive ...

* B. Vascular dysfunction of the failing heart: Impact of neurohormonal blockade Strategies to prevent/reverse HF progression Content points: Maladaptive ...

| PowerPoint PPT presentation | free to view

Vascular Dysfunction: Sequelae of Acute Severe Hypertension PowerPoint PPT Presentation

Vascular Dysfunction: Sequelae of Acute Severe Hypertension - Profile of an ideal parenteral antihypertensive ... Some data suggest that this drug may protect against ... Sequelae of Acute Severe Hypertension Author:

Profile of an ideal parenteral antihypertensive ... Some data suggest that this drug may protect against ... Sequelae of Acute Severe Hypertension Author:

| PowerPoint PPT presentation | free to view

Examining the Science Underlying Myocardial Ischemia PowerPoint PPT Presentation

Examining the Science Underlying Myocardial Ischemia - VPC = ventricular premature contraction VT = ventricular tachycardia Risk factors Age Heredity Gender Smoking Lipids Hypertension Diabetes Obesity Clinical or ...

VPC = ventricular premature contraction VT = ventricular tachycardia Risk factors Age Heredity Gender Smoking Lipids Hypertension Diabetes Obesity Clinical or ...

| PowerPoint PPT presentation | free to view

Insulin Resistance and Cardiovascular Disease: - Title: PowerPoint Presentation Author: MEDCON Last modified by: MEDCON Created Date: 6/7/2004 4:56:07 PM Document presentation format: On-screen Show

Title: PowerPoint Presentation Author: MEDCON Last modified by: MEDCON Created Date: 6/7/2004 4:56:07 PM Document presentation format: On-screen Show

| PowerPoint PPT presentation | free to view

Improving Outcomes in Heart Failure: New Insights From Vascular Biology PowerPoint PPT Presentation

Improving Outcomes in Heart Failure: New Insights From Vascular Biology - Title: PowerPoint Presentation Author: MEDCON Last modified by: IT Dept Created Date: 6/7/2004 4:56:07 PM Document presentation format: On-screen Show

Title: PowerPoint Presentation Author: MEDCON Last modified by: IT Dept Created Date: 6/7/2004 4:56:07 PM Document presentation format: On-screen Show

| PowerPoint PPT presentation | free to view

New Therapeutic Options for Chronic Stable Angina PowerPoint PPT Presentation

New Therapeutic Options for Chronic Stable Angina - Sulfi S, Timmis AD. Ivabradine the first selective sinus node If channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006;60:222-228.

Sulfi S, Timmis AD. Ivabradine the first selective sinus node If channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006;60:222-228.

| PowerPoint PPT presentation | free to view

Critical Role of RAAS in Vasculoprotection: New Science PowerPoint PPT Presentation

Critical Role of RAAS in Vasculoprotection: New Science - Critical Role of RAAS in Vasculoprotection: New Science New aspects of RAAS ACE homologues ACE2 Soluble ACE ACE substrates Ang (1 7) Ang (1 9) N-acetyl-seryl ...

Critical Role of RAAS in Vasculoprotection: New Science New aspects of RAAS ACE homologues ACE2 Soluble ACE ACE substrates Ang (1 7) Ang (1 9) N-acetyl-seryl ...

| PowerPoint PPT presentation | free to view

TNT: New data on intensive lipid lowering in stable CHD patients PowerPoint PPT Presentation

TNT: New data on intensive lipid lowering in stable CHD patients - Title: PowerPoint Presentation Author: Bill Tryon Last modified by: William Tryon Created Date: 6/7/2004 4:56:07 PM Document presentation format: On-screen Show

Title: PowerPoint Presentation Author: Bill Tryon Last modified by: William Tryon Created Date: 6/7/2004 4:56:07 PM Document presentation format: On-screen Show

| PowerPoint PPT presentation | free to view

Effects of Acute BP Elevation on the Vessel Wall PowerPoint PPT Presentation

Effects of Acute BP Elevation on the Vessel Wall - In patients with hypertensive emergency, communication between the emergency department physician and primary care physician is critical to ensure continuity of care.

In patients with hypertensive emergency, communication between the emergency department physician and primary care physician is critical to ensure continuity of care.

| PowerPoint PPT presentation | free to view

ACC/AHA UA/NSTEMI Guidelines: Role of GP IIb/IIIa Inhibitors - ACC/AHA UA/NSTEMI Guidelines: Role of GP IIb/IIIa Inhibitors

ACC/AHA UA/NSTEMI Guidelines: Role of GP IIb/IIIa Inhibitors

| PowerPoint PPT presentation | free to view

Vbwg PowerPoint PPT Presentations